Compound Names

What Is Desmopressin?

Published Oct 15, 2026 · 17 minute read

Desmopressin, sold as DDAVP and in generic forms, is a lab-made version of vasopressin, the hormone that tells the kidneys to conserve water. It has been a US prescription drug since 1978 for central diabetes insipidus, childhood bedwetting and certain bleeding disorders. Its benefits are real but narrow, and its defining risk is hyponatremia: blood sodium diluted by water the body cannot get rid of, which several labels place in a boxed warning.

Medical Supervision Required:Peptide Tracker is for private logging, calculations, reminders, inventory records, and education. It is not medical advice, dosing instruction, prescribing guidance, diagnosis, or a substitute for a qualified healthcare professional.

Key Takeaways

  • Desmopressin is a synthetic analog of vasopressin, the antidiuretic hormone. It makes the kidneys hold on to water and, at higher doses, raises clotting factor VIII.
  • US labels cover central diabetes insipidus, childhood bedwetting (tablets) and bleeding in hemophilia A or type 1 von Willebrand disease with some factor VIII activity. Both low-dose nocturia products are now discontinued.
  • Low blood sodium is the defining risk. Several labels carry a boxed warning, and a US cohort of older adults found a 13-fold higher hyponatremia rate than with oxybutynin.
  • Its plasma half-life is about 2 to 3 hours with normal kidneys, but it reaches 8.7 hours in severe kidney impairment, and the labels contraindicate it below a creatinine clearance of 50 mL/min.
  • It has no anabolic or performance effect. WADA bans it at all times as a masking agent because retained water dilutes blood markers used in doping tests.

Desmopressin shows up in two very different conversations. In medicine, it replaces a missing hormone or briefly boosts a clotting factor. In sport, it appears on the anti-doping list, not because it builds anything, but because retained water dilutes the blood tests used to catch other drugs.

For readers who track peptides or GLP-1 medicines, the practical questions are about water and sodium. This guide covers what the FDA labels, Cochrane reviews and the WADA list report, and what can actually be measured. It is educational and is not medical advice.

Desmopressin at a glance What to know
Other names DDAVP, desmopressin acetate; brands Desmoda, Stimate; Nocdurna and Noctiva (both discontinued)
Class Synthetic vasopressin analog acting mainly on V2 receptors (antidiuretic)
US status Prescription drug, first approved 1978; no DEA schedule on the labels
WADA status Prohibited at all times under S5, diuretics and masking agents
Routes IV, subcutaneous, nasal spray, tablet, sublingual tablet, oral solution
Half-life About 2.8 h after IV dosing; 1.5–2.5 h after tablets; 8.7 h in severe kidney impairment (label data)
Main risk Hyponatremia, which can cause seizures, coma or death
Main evidence gap No evidence of muscle, fat-loss or performance benefit; nocturia gains over placebo are small

1. How does desmopressin work?

Vasopressin, also called antidiuretic hormone, belongs to the small family of hormones made in the hypothalamus and released from the posterior pituitary. A StatPearls overview of posterior pituitary physiology sums up that family’s two jobs as regulating water retention and triggering uterine contractions. Water handling is vasopressin’s job; uterine contraction is the domain of oxytocin, the related posterior-pituitary peptide covered in its own guide.

Desmopressin keeps vasopressin’s basic framework but changes two positions: the starting amino group is removed and one arginine is swapped for its mirror-image D-form. The DDAVP Injection label says these edits lengthen its action and greatly reduce its effects on blood vessels and gut muscle compared with its kidney effect. As a result, the doses used to control urine output normally stay below the level that pushes blood pressure up.

Two effects at two dose levels

Effect Receptor or mechanism What the label reports
Antidiuresis V2 receptors in the kidney’s collecting ducts More water reabsorbed; less, more concentrated urine; lower plasma osmolality, the concentration of dissolved particles in blood
Clotting support Release of factor VIII and von Willebrand factor from blood vessel linings Dose-related rise in factor VIII; 0.4 mcg/kg IV gave peak increases of 300–400%, starting within 30 minutes and peaking at 90 minutes to 2 hours

The clotting effect was first reported in 1977. Mannucci and colleagues gave 0.3 mcg/kg before dental surgery to four people with mild or moderate hemophilia and saw factor VIII activity rise two- to threefold. The label notes the response fades if doses are repeated more often than every 48 hours, a loss of effect called tachyphylaxis.

A note on oxytocin

Because the two hormones are related, oxytocin carries a weaker version of the same water problem. The oxytocin injection label describes an intrinsic antidiuretic effect and warns that it can cause water intoxication, including convulsions. Desmopressin is engineered to make that water-retaining action its main purpose, which is why sodium monitoring sits at the center of its labels.

2. What is desmopressin approved for?

Each US product has its own label, indication and dose. The doses below are as labeled for those conditions; they are not general-use guidance.

Condition Product and route Labeled dosing
Central diabetes insipidus DDAVP Injection, 4 mcg/mL, IV or subcutaneous 2–4 mcg per day in one or two doses
Central diabetes insipidus Desmopressin nasal spray, 10 mcg per spray (age 4 and older) Adults 10–40 mcg per day; children 10–30 mcg per day
Central diabetes insipidus DDAVP Tablets, 0.1 and 0.2 mg Start 0.05 mg twice daily; usual range 0.1–1.2 mg per day in two or three doses
Central diabetes insipidus Desmoda oral solution, 0.05 mg/mL (adults and children) Start 0.05 mg twice daily, then titrate
Bedwetting, age 6 and older DDAVP Tablets 0.2 mg at bedtime, up to 0.6 mg
Hemophilia A or type 1 von Willebrand disease DDAVP Injection, IV infusion 0.3 mcg/kg, maximum 20 mcg, over 15–30 minutes
Hemophilia A or type 1 von Willebrand disease Stimate nasal spray, 150 mcg per spray 300 mcg at 50 kg or more; 150 mcg under 50 kg
Nocturia from nighttime overproduction of urine Nocdurna sublingual tablet (discontinued) Women 27.7 mcg; men 55.3 mcg, 1 hour before bed
Nocturia from nighttime overproduction of urine Noctiva nasal spray (discontinued) 0.83 or 1.66 mcg nightly

Dosing sources: DDAVP Tablets label, generic nasal spray label, Desmoda label, Stimate label, plus the Injection, Nocdurna and Noctiva labels cited elsewhere on this page.

Limits written into the labels

  • Central diabetes insipidus only. It replaces vasopressin the body is not making. It does not help nephrogenic diabetes insipidus, where the kidneys cannot respond to the hormone.
  • Some factor VIII is required. The bleeding indication requires factor VIII activity above 5% and excludes the severe form of type 1 von Willebrand disease. In the type 2B form, the label warns of platelet clumping, a falling platelet count and possible thrombosis.
  • No nasal spray for bedwetting. The spray label leaves out that use because, after marketing, low-sodium cases and related seizures were reported more often with the spray than with the tablets.

Which products are still marketed

Drugs@FDA lists Desmoda, approved February 25, 2026, as a current prescription product alongside DDAVP Injection and DDAVP Tablets. Nocdurna, Noctiva, Stimate and the brand DDAVP Nasal Spray are listed as discontinued, while generic 10 mcg sprays remain on DailyMed.

3. What did the clinical trials show?

Bedwetting in children

The tablet approval rested on two placebo-controlled trials in 340 children aged 5 to 17, treated for two weeks. Every group started at about 10 or 11 wet nights per fortnight.

Group Children Drop in wet nights from baseline
Placebo 85 10%
0.2 mg 79 27%
0.4 mg 82 30%
0.6 mg 83 40%

All three doses beat placebo, according to the DDAVP Tablets label. The much larger 2025 Cochrane review by Hahn and colleagues pooled 95 trials and 8,473 children.

Comparison Result Certainty
Wet nights per week vs placebo About 1.8 fewer (MD −1.81, 95% CI −2.24 to −1.39; 16 trials) Low
14 dry nights in a row vs placebo About three times as likely (RR 3.18, 95% CI 1.75–5.80; 11 trials) Moderate
14 dry nights in a row vs bedwetting alarm Little or no difference (RR 0.98, 95% CI 0.88–1.09; 15 trials) Low

Nocturia in adults

Nocturia means waking at night to urinate. The two Nocdurna trials lasted three months and enrolled 237 women and 230 men who got up at least twice a night because more than a third of their daily urine was made overnight.

Outcome Women: placebo Women: 27.7 mcg Men: placebo Men: 55.3 mcg
Night voids at start 2.9 2.9 3.0 3.0
Change by end of trial −1.2 −1.5 −0.9 −1.3
Gap vs placebo (95% CI) — −0.3 (−0.5 to −0.1) — −0.4 (−0.6 to −0.2)
Chance of at least 33% fewer voids 0.62 0.78 0.50 0.67

Source: Nocdurna label. The Noctiva label reported a similar gap in adults aged 50 and older: 0.3 to 0.4 fewer voids per night than placebo on the 1.66 mcg dose.

The pattern matters. Placebo groups improved substantially, and the drug added less than half a trip to the bathroom per night. A Cochrane analysis pooling 14 trials and 2,966 men estimated 0.85 fewer voids per night over 3 to 12 months, on low-quality evidence, and found no extra benefit from adding an alpha-blocker or an anticholinergic.

Surgical bleeding without a bleeding disorder

Using desmopressin to cut blood loss during surgery is off-label. A Cochrane review of 65 trials and 3,874 participants found adult cardiac surgery patients needed 0.52 fewer units of red cells (95% CI −0.96 to −0.08), which the authors judged unlikely to matter clinically. The share of people transfused barely changed (RR 0.96, 95% CI 0.86–1.06), and estimates for death (Peto OR 1.09) and clotting events (Peto OR 1.36) had wide confidence intervals that included no effect.

4. How long does desmopressin last in the body?

Desmopressin is a peptide, so the gut destroys almost all of an oral dose. That explains why tablets are dosed in tenths of a milligram while injections are dosed in micrograms. The bioavailability guide explains the general idea.

Measure Value Label
Terminal half-life, IV, normal kidneys 2.8 h DDAVP Injection
Plasma half-life, tablets 1.5–2.5 h, regardless of dose DDAVP Tablets
Tablet bioavailability About 0.16% of an IV dose; about 5% of a nasal dose DDAVP Tablets
Sublingual bioavailability 0.25% (95% CI 0.21–0.31%) Nocdurna
Time to peak level 0.9–1.5 h by mouth or nose DDAVP Tablets
Water-retaining effect of tablets Begins in about 1 h, peaks at 4–7 h, lasts up to 8 h at 0.1–0.2 mg DDAVP Tablets
High-fat meal (oral solution) Peak level 72% lower; total exposure 64% lower Desmoda
Liver metabolism Not processed by CYP450 enzymes DDAVP Injection
Urinary excretion 52% of a 2 mcg IV dose excreted unchanged within 24 h DDAVP Injection

Note the gap between the two timings. Blood levels halve every few hours, yet the antidiuretic effect of a tablet can persist for up to 8 hours, which is why the labeled fluid limit runs well past the dose. A half-life curve describes concentration, not how long the kidney keeps holding water.

Kidney function changes everything

The kidneys clear desmopressin. When the label’s investigators gave a single 2 mcg IV dose to 24 people with varying kidney function, exposure climbed steeply as function fell.

Kidney function Half-life Exposure (AUC) vs normal
Normal 2.8 h 1×
Mild impairment 4 h 1.5×
Moderate impairment 6.6 h 2.4×
Severe impairment 8.7 h 3.6×

The labels contraindicate desmopressin when creatinine clearance, an estimate of kidney filtering capacity, is below 50 mL/min.

5. Why is low sodium the main danger?

The mechanism is mechanical. The drug blocks the kidney’s usual route for dumping extra water, so anything a person drinks beyond what they lose stays in the bloodstream and dilutes its sodium. To limit this, the labels restrict fluids from 1 hour before a dose to 8 hours after, extended to 24 hours for Stimate.

What the boxed warning requires

The DDAVP Injection label, revised in 2022, carries a boxed warning shared by Nocdurna and Noctiva. It states that severe hyponatremia can lead to seizures, coma, respiratory arrest or death, and it rules out use in people at higher risk. Before the first dose, blood sodium should be in the normal range; it is then rechecked within a week, again at roughly one month and periodically after that, more often from age 65. Treatment may need to stop temporarily or permanently if sodium falls.

Labels without a box, including those for the tablets, generic sprays, Stimate and Desmoda, still warn that the condition can be fatal. Desmoda’s label, and the tablet label for bedwetting, tell users to pause during fever, vomiting, diarrhea, extreme heat, vigorous exercise or anything else that drives up water intake. Symptoms the labels list as warning signs include weight gain, headache, confusion, restlessness, tiredness, nausea or vomiting, weakness and muscle cramps.

How often sodium dropped in trials

Blood sodium Women, placebo (n = 171) Women, 27.7 mcg (n = 191) Men, placebo (n = 207) Men, 55.3 mcg (n = 192)
130–134 mmol/L 4% 7% 3% 17%
126–129 mmol/L 0% 4% 0% under 1%
125 mmol/L or lower under 1% 0% 0% 2%

These pooled numbers come from the Nocdurna label. In men aged 65 and older on 55.3 mcg, 23% reached the 130–134 range and 3% fell to 125 or below. Women receive the lower dose because they are more sensitive to the drug.

Real-world rates were far higher

Trials enroll carefully screened patients. In routine US care, Fralick and colleagues matched 3,137 adults with a mean age of 70 who started older desmopressin formulations against 3,137 who started oxybutynin, another bladder drug.

Measure Desmopressin Oxybutynin
Hyponatremia per 1,000 person-years 146 11
Hazard ratio (95% CI) 13.19 (6.69–26.01) Reference
Baseline sodium measured 20% of patients —

The last row is the uncomfortable one: the current boxed warning calls for a normal sodium before starting, yet four in five patients in this cohort had no baseline measurement.

Other labeled risks

  • Blood pressure shifts. Pressure may drop, with a quicker pulse, or rise; the injection label asks for monitoring when the drug is given intravenously.
  • Fluid overload. Retained water can worsen heart failure or uncontrolled hypertension, both contraindications on the injection label.
  • Allergic reactions. Reports of anaphylaxis exist for both the IV and nasal forms, and some IV cases were fatal.
  • Unreliable nasal absorption. A scarred, swollen or otherwise diseased nasal lining can make spray doses absorb unpredictably.
  • Common effects. Headache, nausea, flushing and mild stomach cramps; sprays add congestion, rhinitis and nosebleeds.

6. Interactions, and where GLP-1 users should pay attention

Under the DDAVP Injection label, desmopressin should not be used by anyone with a history of hyponatremia or a current low sodium, kidney function below a creatinine clearance of 50 mL/min, habitual excessive drinking (polydipsia), heart failure, uncontrolled hypertension, or known or suspected SIADH, a condition in which the body makes too much antidiuretic hormone. The label also excludes people taking a loop diuretic like furosemide or a glucocorticoid by mouth, injection or inhaler, and anyone with an illness that disrupts fluid or electrolyte balance, for example gastroenteritis or a systemic infection.

Closer sodium monitoring is advised with a long list of common medicines: SSRIs and tricyclic antidepressants, chlorpromazine, opioids, NSAIDs, thiazide diuretics, the anticonvulsants carbamazepine and lamotrigine, oxybutynin, and sulfonylureas, chlorpropamide in particular. The tablet label mentions rare hyponatremic seizures when combined with oxybutynin or imipramine. Since desmopressin bypasses CYP450 liver enzymes, the usual enzyme-based interactions are not expected.

Overlap with semaglutide and other GLP-1 drugs

No study cited here tested desmopressin together with a GLP-1 medicine, and the DDAVP Injection label does not name that drug class. The overlap is in side effects and monitoring rather than in a known chemical interaction.

Issue GLP-1 side of the overlap Desmopressin side of the overlap
Vomiting and diarrhea The Ozempic label links most reported acute kidney injury to dehydration from nausea, vomiting or diarrhea, and advises checking kidney function, especially during dose escalation Labels say to pause during vomiting or diarrhea and contraindicate use during illnesses that disturb fluid balance
Kidney function Same Ozempic warning on volume depletion Clearance falls and half-life lengthens with kidney impairment; contraindicated below 50 mL/min
Sulfonylureas The Ozempic label warns of a higher risk of low blood sugar when semaglutide is combined with a sulfonylurea or insulin Sulfonylureas are on the desmopressin labels’ list for closer sodium monitoring
Oral absorption The Ozempic label says slower stomach emptying may affect absorption of oral medicines taken with it Oral desmopressin is absorbed poorly to begin with, and a high-fat meal sharply reduced exposure to the Desmoda solution; no data exist on GLP-1 co-use

None of this establishes that the combination is unsafe; it means the situations that each label flags line up. Anyone prescribed both is in the territory where a prescriber, not a self-adjusted schedule, decides on sodium and kidney checks.

7. Is desmopressin banned in sport, and does it boost performance?

The WADA 2026 Prohibited List places desmopressin in class S5, diuretics and masking agents, together with diuretics, vaptans, IV plasma expanders and probenecid. It is banned in and out of competition and counts as a Specified Substance; the class exempts only felypressin used locally in dental anesthesia. Finding a masking agent alongside any amount of certain threshold substances, such as salbutamol or pseudoephedrine, is an adverse finding unless an exemption covers both.

The reason is dilution. In a crossover experiment, Sanchis-Gomar and colleagues gave 8 active men desmopressin plus 1.5 L of water on one day and the water alone on another. With desmopressin, hematocrit, hemoglobin and the OFF-hr score, a composite used to screen for blood doping, all fell significantly. Concentrations of albumin, glucose, creatinine and total protein dropped too.

There is no evidence of a benefit in return. When Inder’s group gave 8 male triathletes 20 mcg of nasal desmopressin before hard exercise, it neither produced extra hydration nor improved performance compared with control. Anti-doping labs screen urine for it by liquid chromatography–mass spectrometry, with one published initial-testing method reporting detection limits of 50–200 pg/mL.

Desmopressin has no anabolic effect and no documented muscle or fat-loss effect. Combining a drug that blocks water excretion with heavy drinking or hard training recreates exactly the conditions the labels warn about.

8. What can you meaningfully measure or track?

Most of desmopressin’s safety story can be followed with ordinary measurements, which makes good records useful when discussing treatment with a clinician.

What to record Why it matters Source of the concern
Serum sodium results and dates Labels set a schedule: before starting, within 7 days, at about 1 month, then periodically DDAVP Injection boxed warning
Body weight, especially sudden gains Weight gain is a listed warning sign of hyponatremia, distinct from fat change Desmopressin labels
Fluid intake around each dose Labels restrict fluids from 1 hour before to 8 hours after (24 hours for Stimate) Desmopressin labels
Episodes of vomiting, diarrhea or fever Triggers for pausing treatment under some labels; also a GLP-1 dehydration warning Tablet, Desmoda and Ozempic labels
Night-time voids The outcome measured in nocturia trials; the benefit over placebo was under half a void per night Nocdurna label; Han et al.
Kidney function results Half-life and exposure rise as kidney function falls DDAVP Injection label
New medicines Many common drug classes call for closer sodium monitoring DDAVP Injection label

Two cautions apply. First, a night-time void diary can show improvement on placebo too, so a personal before-and-after change cannot separate drug effect from expectation. Second, the Sanchis-Gomar experiment shows that water retention can lower concentration-based blood values in the short term, so lab results drawn during treatment reflect hydration as well as the underlying measure.

A shared log of doses, fluid timing, weight and lab results is easier to review than scattered notes. The peptide tracking guide covers practical ways to keep those records together; it does not replace the sodium checks the labels require.

9. Desmopressin FAQ

  • What is desmopressin used for?

    US labels approve it for central diabetes insipidus, primary nocturnal enuresis (bedwetting) in children aged 6 and older using the tablets, and bleeding in hemophilia A or type 1 von Willebrand disease when factor VIII activity is above 5%. Two low-dose nocturia products were approved in 2017 and 2018 and are now listed as discontinued.

  • Is desmopressin the same as vasopressin?

    No. It is a modified version of vasopressin. The changes make it last longer and act mainly on the kidney's water-retaining V2 receptors, with much less effect on blood vessels than the natural hormone at usual doses.

  • What are the side effects of desmopressin?

    The serious one is hyponatremia, low blood sodium from retained water, which can cause seizures, coma and death. Labels also list headache, nausea, flushing, mild abdominal cramps, blood pressure changes and allergic reactions; nasal sprays add congestion and nosebleeds.

  • How long does desmopressin stay in your system?

    The labels report a terminal half-life of about 2.8 hours after an IV dose and 1.5 to 2.5 hours after tablets in people with normal kidneys. The water-retaining effect of tablets can last up to 8 hours. In severe kidney impairment the half-life rose to 8.7 hours.

  • Can desmopressin be used with semaglutide?

    No study cited here tested the combination, and the DDAVP Injection label does not name GLP-1 drugs. The overlap is practical: the Ozempic label links vomiting and diarrhea to dehydration and kidney injury, while desmopressin labels say to pause or avoid treatment during vomiting, diarrhea or illnesses that disturb fluid balance. Any combined use belongs with a prescriber who can check sodium and kidney function.

  • Does desmopressin cause weight gain?

    It causes water retention, not fat gain. The labels list weight gain among the warning signs of hyponatremia, so a sudden rise on the scale while taking it is a reason to contact a clinician rather than a body-composition change.

  • Is desmopressin banned in sports?

    Yes. The WADA 2026 Prohibited List places it in class S5, diuretics and masking agents, prohibited in and out of competition. It is a Specified Substance.

  • Why do you have to limit fluids while taking desmopressin?

    Desmopressin stops the kidneys from clearing extra water. Drinking normally on top of that dilutes blood sodium. The labels restrict fluids from 1 hour before a dose until 8 hours after, or 24 hours for the high-dose Stimate spray.

10. Sources

References used for this article

Download for iOS